PKN2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL363119	0.44	5/20
SCHEMBL414672	0.41	5/20
SCHEMBL363116	0.39	5/20
SCHEMBL369534	0.39	5/20
SCHEMBL369535	0.39	5/20
SCHEMBL363855	0.36	5/20
SCHEMBL364346	0.36	5/20
Y-27632 (SCHEMBL190356)	1.00	4/20
Ucn-01 (SCHEMBL259162)	1.00	4/20
SCHEMBL307449	1.00	4/20
Tofacitinib (SCHEMBL322753)	1.00	4/20
Y-27632 (SCHEMBL342816)	1.00	4/20
Y-27632 (SCHEMBL364637)	0.97	4/20
Y-27632 (SCHEMBL364638)	0.97	4/20
SCHEMBL307709	0.81	4/20
SCHEMBL353500	0.75	4/20
Ridinilazole (SCHEMBL413723)	0.66	4/20
SCHEMBL316190	0.60	4/20
SCHEMBL352332	0.60	4/20
SCHEMBL351447	0.59	4/20

Clinical trials — most relevant to PKN2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds	PHASE2/PHASE3	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI	PHASE2	COMPLETED
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pyruvate Kinase Deficiency Global Longitudinal Registry	nan	ACTIVE_NOT_RECRUITING
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Pediatric Cardiomyopathy Mutation Analysis	nan	RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Microvascular Dysfunction and the Development of Whole-body Insulin Resistance	nan	COMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases	nan	UNKNOWN
Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)	nan	RECRUITING
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
A Biorepository for Coronary Heart Disease in Qatar	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PKN2 binder may also engage these)

Protein	Name	Similarity
Q8BWW9	—	1.000	Q8BWW9 →
A7MBL8	—	1.000	A7MBL8 →
O08874	—	1.000	O08874 →
Q9ESL4	—	0.985	Q9ESL4 →
PRKD1	Serine/threonine-protein kinase D1	0.985	landscape →
Q8BPM2	—	0.985	Q8BPM2 →
Q8K1Y2	—	0.984	Q8K1Y2 →
PRKD3	Serine/threonine-protein kinase D3	0.983	landscape →
MAP4K5	Mitogen-activated protein kinase kinase kinase kinase 5	0.983	landscape →
P34908	—	0.982	P34908 →
MAP3K20	Mitogen-activated protein kinase kinase kinase 20	0.982	landscape →
Q04982	—	0.981	Q04982 →
P28028	—	0.981	P28028 →
Q99JP0	—	0.981	Q99JP0 →
A6NI28	—	0.980	A6NI28 →
MAP4K3	Mitogen-activated protein kinase kinase kinase kinase 3	0.980	landscape →
Q62101	—	0.979	Q62101 →
Q6PCS4	—	0.979	Q6PCS4 →
Q8QFR2	—	0.979	Q8QFR2 →
Q9WTQ1	—	0.979	Q9WTQ1 →
B2RQE8	—	0.978	B2RQE8 →
Q641K1	—	0.978	Q641K1 →
Q5R6M6	—	0.978	Q5R6M6 →
Q7YQL6	—	0.977	Q7YQL6 →
F1LXF1	—	0.977	F1LXF1 →
Q9H8E8	—	0.977	Q9H8E8 →
O35099	—	0.977	O35099 →
BCR	Breakpoint cluster region protein	0.977	landscape →
KIF23	Kinesin-like protein KIF23	0.976	landscape →
Q920M7	—	0.976	Q920M7 →